These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

271 related articles for article (PubMed ID: 24886365)

  • 1. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: preclinical activity in HER2 non-amplified inflammatory breast cancer models.
    Mu Z; Klinowska T; Dong X; Foster E; Womack C; Fernandez SV; Cristofanilli M
    J Exp Clin Cancer Res; 2014 May; 33(1):47. PubMed ID: 24886365
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor, ERBB2 (HER2), and ERBB3: a unique agent for simultaneous ERBB receptor blockade in cancer.
    Hickinson DM; Klinowska T; Speake G; Vincent J; Trigwell C; Anderton J; Beck S; Marshall G; Davenport S; Callis R; Mills E; Grosios K; Smith P; Barlaam B; Wilkinson RW; Ogilvie D
    Clin Cancer Res; 2010 Feb; 16(4):1159-69. PubMed ID: 20145185
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sustained Inhibition of HER3 and EGFR Is Necessary to Induce Regression of HER2-Amplified Gastrointestinal Carcinomas.
    Leto SM; Sassi F; Catalano I; Torri V; Migliardi G; Zanella ER; Throsby M; Bertotti A; Trusolino L
    Clin Cancer Res; 2015 Dec; 21(24):5519-31. PubMed ID: 26296355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining AZD8931, a novel EGFR/HER2/HER3 signalling inhibitor, with AZD5363 limits AKT inhibitor induced feedback and enhances antitumour efficacy in HER2-amplified breast cancer models.
    Crafter C; Vincent JP; Tang E; Dudley P; James NH; Klinowska T; Davies BR
    Int J Oncol; 2015 Aug; 47(2):446-54. PubMed ID: 26095475
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of EGFR, HER2 and HER3 signaling with AZD8931 alone and in combination with paclitaxel: phase i study in Japanese patients with advanced solid malignancies and advanced breast cancer.
    Kurata T; Tsurutani J; Fujisaka Y; Okamoto W; Hayashi H; Kawakami H; Shin E; Hayashi N; Nakagawa K
    Invest New Drugs; 2014 Oct; 32(5):946-54. PubMed ID: 24875132
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors.
    Tjulandin S; Moiseyenko V; Semiglazov V; Manikhas G; Learoyd M; Saunders A; Stuart M; Keilholz U
    Invest New Drugs; 2014 Feb; 32(1):145-53. PubMed ID: 23589215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistance.
    Morrison G; Fu X; Shea M; Nanda S; Giuliano M; Wang T; Klinowska T; Osborne CK; Rimawi MF; Schiff R
    Breast Cancer Res Treat; 2014 Apr; 144(2):263-72. PubMed ID: 24554387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial.
    Adams R; Brown E; Brown L; Butler R; Falk S; Fisher D; Kaplan R; Quirke P; Richman S; Samuel L; Seligmann J; Seymour M; Shiu KK; Wasan H; Wilson R; Maughan T;
    Lancet Gastroenterol Hepatol; 2018 Mar; 3(3):162-171. PubMed ID: 29254887
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ZD1839, a specific epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, induces the formation of inactive EGFR/HER2 and EGFR/HER3 heterodimers and prevents heregulin signaling in HER2-overexpressing breast cancer cells.
    Anido J; Matar P; Albanell J; Guzmán M; Rojo F; Arribas J; Averbuch S; Baselga J
    Clin Cancer Res; 2003 Apr; 9(4):1274-83. PubMed ID: 12684395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Human breast cancer cells harboring a gatekeeper T798M mutation in HER2 overexpress EGFR ligands and are sensitive to dual inhibition of EGFR and HER2.
    Rexer BN; Ghosh R; Narasanna A; Estrada MV; Chakrabarty A; Song Y; Engelman JA; Arteaga CL
    Clin Cancer Res; 2013 Oct; 19(19):5390-401. PubMed ID: 23948973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibition of EGFR, HER2, and HER3 signaling with AZD8931 in combination with anastrozole as an anticancer approach: Phase II randomized study in women with endocrine-therapy-naïve advanced breast cancer.
    Johnston S; Basik M; Hegg R; Lausoontornsiri W; Grzeda L; Clemons M; Dreosti L; Mann H; Stuart M; Cristofanilli M
    Breast Cancer Res Treat; 2016 Nov; 160(1):91-99. PubMed ID: 27654971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effects of the novel, reversible epidermal growth factor receptor/ErbB-2 tyrosine kinase inhibitor, GW2016, on the growth of human normal and tumor-derived cell lines in vitro and in vivo.
    Rusnak DW; Lackey K; Affleck K; Wood ER; Alligood KJ; Rhodes N; Keith BR; Murray DM; Knight WB; Mullin RJ; Gilmer TM
    Mol Cancer Ther; 2001 Dec; 1(2):85-94. PubMed ID: 12467226
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers.
    Osada T; Hartman ZC; Wei J; Lei G; Hobeika AC; Gwin WR; Diniz MA; Spector N; Clay TM; Chen W; Morse MA; Lyerly HK
    Breast Cancer Res; 2018 Aug; 20(1):90. PubMed ID: 30092835
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.
    Dupouy S; Doan VK; Wu Z; Mourra N; Liu J; De Wever O; Llorca FP; Cayre A; Kouchkar A; Gompel A; Forgez P
    Oncotarget; 2014 Sep; 5(18):8235-51. PubMed ID: 25249538
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Metastasis Suppressor, N-MYC Downstream-regulated Gene-1 (NDRG1), Down-regulates the ErbB Family of Receptors to Inhibit Downstream Oncogenic Signaling Pathways.
    Kovacevic Z; Menezes SV; Sahni S; Kalinowski DS; Bae DH; Lane DJ; Richardson DR
    J Biol Chem; 2016 Jan; 291(3):1029-52. PubMed ID: 26534963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.
    Gupta P; Srivastava SK
    BMC Med; 2012 Jul; 10():80. PubMed ID: 22824293
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.
    Chen J; Kinoshita T; Sukbuntherng J; Chang BY; Elias L
    Mol Cancer Ther; 2016 Dec; 15(12):2835-2844. PubMed ID: 27678331
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Metabolic disposition of AZD8931, an oral equipotent inhibitor of EGFR, HER2 and HER3 signalling, in rat, dog and man.
    Ballard P; Swaisland HC; Malone MD; Sarda S; Ghiorghiu S; Wilbraham D
    Xenobiotica; 2014 Dec; 44(12):1083-98. PubMed ID: 25007130
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of HER3 by a novel antisense oligonucleotide, EZN-3920, improves the antitumor activity of EGFR and HER2 tyrosine kinase inhibitors in animal models.
    Wu Y; Zhang Y; Wang M; Li Q; Qu Z; Shi V; Kraft P; Kim S; Gao Y; Pak J; Youngster S; Horak ID; Greenberger LM
    Mol Cancer Ther; 2013 Apr; 12(4):427-37. PubMed ID: 23395887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neurotensin (NTS) and its receptor (NTSR1) causes EGFR, HER2 and HER3 over-expression and their autocrine/paracrine activation in lung tumors, confirming responsiveness to erlotinib.
    Younes M; Wu Z; Dupouy S; Lupo AM; Mourra N; Takahashi T; Fléjou JF; Trédaniel J; Régnard JF; Damotte D; Alifano M; Forgez P
    Oncotarget; 2014 Sep; 5(18):8252-69. PubMed ID: 25249545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.